SynthesisSystematic reviews2025
Predicting fibroblast activation protein overexpression in the overall survival rate of cancer patients: a systematic review and meta-analysis.
Synthesis in Systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic targeting of cancer-associated fibroblasts with oncolytic virus in preclinical models of intrahepatic cholangiocarcinoma.Molecular therapy. Oncology · 2026Article
- The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications.International journal of molecular sciences · 2026Review
- A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [EJNMMI radiopharmacy and chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionFibroblast activation protein-alpha (FAP-α) is a vital surface marker of cancer-associated fibroblasts, and its high expression is associated with distant metastasis. This systematic review and meta-analysis were performed to predict the role of FAP-α overexpression in the overall survival rate of cancer patients.
methodsThis systematic review and meta-analysis were first performed on studies published in online databases, including PubMed, Scopus, and Web of Sciences, based on the PRISMA framework. We focused on all cancer patients with reported FAP-α expression levels and survival rate outcomes. Two reviewers independently conducted study selection and data extraction, and discrepancies were resolved through group discussion. Pooled hazard ratios (HRs) were then calculated by the fixed-effect and random-effects models to determine the association between FAP-α with crude HR (univariable), adjusted HR (multivariable), progression-free survival, and disease-free survival.
resultsForty-one studies were included in the systematic review, and 25 were included in the meta-analysis. Meta-analysis showed that high FAP-α expression was associated with the pooled HR for overall survival (HR = 1.49, 95% CI: 1.19-1.85, P < 0.001) and HR of 1.53 in studies that reported the adjusted effect of high FAP-α expression on overall survival (HR = 1.53, 95% CI: 1.16-2.03, P = 0.003), and HR of 1.36 for disease-free survival (HR = 1.36, 95% CI: 0.750-2.469, P = 0.31). In addition, lymph node metastasis and distant metastasis were significant factors and had pooled HRs of 2.053 (95% CI: 1.603-2.630, P < 0.001) and 2.630 (95% CI: 1.902-3.637, P < 0.001), respectively.
conclusionsOur results showed that cancer patients with FAP-α overexpression had a significant association with poor overall survival. Incorporating FAP-α testing into cancer diagnostic protocols can help identify high-risk patients requiring more critical treatment interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.